(22551) A single arm, open-label, multicenter Phase 2 study of regorafenib in participants who have been treated in a previous Bayer-sponsored regorafenib study (monotherapy or combination treatment) that has reached the primary completion endpoint, or main data analysis, or has been stopped prematurely.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507084-19-00

Acronym

22551

Enrollment

Registered

2024-02-19

Start date

2024-03-07

Completion date

Unknown

Last updated

2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid malignant tumors

Brief summary

Number of participants with serious adverse events (SAEs) and protocol-specified AEs and their severity

Detailed description

Number of participants with dose modifications

Interventions

DRUGBAY 734506

DRUGBAY 73-4506

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of participants with serious adverse events (SAEs) and protocol-specified AEs and their severity	—

Secondary

Measure	Time frame
Number of participants with dose modifications	—

Countries

France, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026